Exploring Treatment Options After Lung Cancer Surgery

V
Vijaya L. Kakani, MD

Primary Investigator

Exploring Treatment Options After Lung Cancer Surgery
Recruiting
18 years - 100 years
All
Phase 3
2 participants needed
1 Location

Brief description of study

Do you have non-small cell lung cancer (NSCLC) but the cancer was not fully removed by surgery? You may qualify for a study exploring treatment options for NSCLC.

This research study is testing whether adding a medication called sacituzumab tirumotecan to pembrolizumab after surgery may help prevent non-small cell lung cancer (NSCLC) from returning in people whose cancer was not completely removed by surgery. 

You may be able to take part if you:

  • Are an adult diagnosed with non-small cell lung cancer (NSCLC)
  • Have had surgery for NSCLC
  • Did not have a complete response after surgery
  • Are eligible to receive pembrolizumab

Detailed description of study

If you join the study, this is what you can expect:

  • You will receive either pembrolizumab alone or in combination with an investigational medication. Pembrolizumab is a type of immunotherapy that helps the immune system fight cancer.
  • The study will measure how well these treatments work by comparing how long each treatment helps keep the cancer from coming back.

You may take part in this study for about 5 to 10 years, including treatment and follow-up.

The study includes:

  • A screening period (up to 28 days) to see if you qualify
  • Treatment before surgery (up to 12 weeks), if surgery is part of your care
  • Surgery, with study visits before and after
  • Treatment after surgery for about 10½ months, if you are eligible
  • Follow-up visits or phone check-ins after treatment ends

Visit schedules vary depending on your study group and medical needs, but most visits happen every 2 to 6 weeks during treatment. After treatment ends, the study team will continue to check in with you periodically.

The study doctor will review all options with you and answer any questions before each step.

You will receive $50 for each study visit you complete to thank you for your time. Reasonable travel costs related to study visits may also be covered. The study doctor or staff will explain the reimbursement process to you.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Non-Small Cell Lung Cancer, NSCLC
  • Age: 18 years - 100 years
  • Gender: All

Inclusion Criteria (you may be eligible if you):

  • Have a diagnosis of non-small cell lung cancer (NSCLC)
  • Have Stage II or Stage III lung cancer that can be treated with surgery
  • Are able to have surgery, based on your doctor’s opinion
  • Have already received or can receive standard treatment before surgery
  • Did not have all cancer removed by surgery
  • Are currently cancer-free on scans after surgery
  • Are well enough to attend regular study visits and receive treatment

Exclusion Criteria (you may not be eligible if you):

  • Have a different type of lung cancer (such as small cell lung cancer)
  • Have serious nerve problems, severe eye disease, or active bowel disease
  • Have uncontrolled heart, lung, or major medical conditions
  • Have an active autoimmune disease needing ongoing treatment
  • Have an active infection or certain untreated viral infections
  • Have received other cancer treatments too recently
  • Have had an organ or tissue transplant
  • Are still recovering from major surgery or have ongoing surgical complications

Updated on 11 Feb 2026. Study ID: ARN-MERCK-MK2870-019, 24266

Pre-Screener

Check if you are eligible Enter contact details Select a study center Select best time to contact

Have you been diagnosed with stage 2 or 3 Non-Small Cell Lung Cancer (NSCLC)?


Preview complete

The prescreener preview is complete. You may now close the preview.

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the Study Team